David Agus | Academic Influence

David Agus's AcademicInfluence.com Rankings

David Agus

Philosophy

#11090

World Rank

#15227

Historical Rank

#2093

USA Rank

Logic

#8379

World Rank

#10482

Historical Rank

#1379

USA Rank

philosophy Degrees

Download Badge

Philosophy

David Agus's Degrees

Bachelors Molecular Biology Princeton University

Why Is David Agus Influential?

(Suggest an Edit or Addition)

According to Wikipedia, David B. Agus is an American physician, cancer researcher and author who serves as a professor of medicine and engineering at the University of Southern California Keck School of Medicine and Viterbi School of Engineering and the Founding Director and CEO of the Lawrence J. Ellison Institute for Transformative Medicine. He is also the cofounder of several personalized medicine companies and a contributor to CBS News on health topics. He is also the author of four books.

(See a Problem?)

David Agus's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A Cross-platform Toolkit for Mass Spectrometry and Proteomics (2012) (2185)
ProteoWizard: open source software for rapid proteomics tools development (2008) (1523)
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. (2002) (884)
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. (2000) (620)
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. (2002) (463)
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. (2005) (398)
Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. (1997) (317)
Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. (1999) (290)
Reentry of T cells to the adult thymus is restricted to activated T cells (1991) (276)
Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. (1999) (270)
Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. (2003) (234)
Dehydroascorbic acid, a blood–brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental stroke (2001) (226)
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. (2004) (201)
Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. (1999) (183)
Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. (2011) (175)
Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model, CWR22-R (2000) (169)
HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. (2001) (166)
Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. (1999) (158)
A physical sciences network characterization of non-tumorigenic and metastatic cells (2013) (157)
The current state of preclinical prostate cancer animal models (2008) (136)
Multiparameter computational modeling of tumor invasion. (2009) (134)
Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. (2001) (130)
Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes (2009) (126)
Future cancer research priorities in the USA: a Lancet Oncology Commission. (2017) (125)
Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. (2010) (121)
CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom’s Macroglobulinemia (2001) (120)
Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. (2015) (114)
Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. (2002) (111)
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. (2007) (99)
Deep learning-enabled breast cancer hormonal receptor status determination from base-level H&E stains (2020) (99)
Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostrate cancer: A phase I/II, open-label study. (2010) (91)
CVS‐3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts (2004) (91)
Epithelial membrane protein-1 is a biomarker of gefitinib resistance. (2005) (88)
Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium (2012) (80)
TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells (2002) (79)
Cancer-Associated Fibroblasts Derived from EGFR-TKI–Resistant Tumors Reverse EGFR Pathway Inhibition by EGFR-TKIs (2010) (79)
Aligning incentives to fulfil the promise of personalised medicine (2015) (76)
2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth (2005) (74)
A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer (2007) (73)
Targeting the HER-kinase axis in cancer. (2004) (72)
Phase I/II Study of Bortezomib Plus Docetaxel in Patients with Advanced Androgen-Independent Prostate Cancer (2007) (72)
The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells (2015) (69)
Anterior gradient 2 (AGR2): Blood‐based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype (2013) (69)
Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors. (2000) (68)
Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies (2005) (67)
Profound atrophy of the bone marrow reflecting major histocompatibility complex class II-restricted destruction of stem cells by CD4+ cells (1994) (67)
HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. (2010) (64)
Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. (1998) (63)
HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. (2000) (60)
Evolutionary Modeling of Combination Treatment Strategies To Overcome Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer (2011) (60)
Deep learned tissue “fingerprints” classify breast cancers by ER/PR/Her2 status from H&E images (2020) (53)
β-2-Microglobulin Is an Androgen-Regulated Secreted Protein Elevated in Serum of Patients with Advanced Prostate Cancer (2007) (51)
Precursor-ion mass re-estimation improves peptide identification on hybrid instruments. (2008) (50)
Predictors of affect following treatment decision‐making for prostate cancer: conversations, cognitive processing, and coping (2009) (49)
A high-content image-based method for quantitatively studying context-dependent cell population dynamics (2016) (47)
Raloxifene, an oestrogen‐receptor‐β‐targeted therapy, inhibits androgen‐independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial (2006) (46)
A potential role for activated HER-2 in prostate cancer. (2000) (46)
Intolerance of uncertainty, cognitive complaints, and cancer‐related distress in prostate cancer survivors (2015) (42)
Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 Trial). (2014) (39)
A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours. (2006) (39)
Design and rationale for the Influenza vaccination After Myocardial Infarction (IAMI) trial. A registry-based randomized clinical trial. (2017) (39)
Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer (2014) (39)
Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma. (2004) (39)
Safety, efficacy, and pharmacodynamics of the investigational agent orteronel (TAK-700) in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study. (2011) (38)
Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. (2002) (36)
A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors (2012) (35)
Body image predicts quality of life in men with prostate cancer (2013) (35)
Effects of the herbal extract PC-SPES on microtubule dynamics and paclitaxel-mediated prostate tumor growth inhibition. (2002) (31)
CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia. (2001) (30)
A Plasma-Based Protein Marker Panel for Colorectal Cancer Detection Identified by Multiplex Targeted Mass Spectrometry (2016) (30)
Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer. (2007) (27)
Clinical proteomics: the promises and challenges of mass spectrometry-based biomarker discovery. (2006) (25)
Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study. (2011) (24)
Workgroup 2: Human xenograft models of prostate cancer (1998) (24)
Correlating nuclear morphometric patterns with estrogen receptor status in breast cancer pathologic specimens (2018) (23)
Update on HER-kinase-directed therapy in prostate cancer. (2004) (22)
Phase 2 Trial of Monoamine Oxidase Inhibitor Phenelzine in Biochemical Recurrent Prostate Cancer (2020) (22)
Quantifying differences in cell line population dynamics using CellPD (2016) (21)
The Value of Diagnostic Testing in Personalized Medicine (2013) (20)
A human homeobox gene, HB24, inhibits development of CD4+ T cells and impairs thymic involution in transgenic mice. (1993) (18)
Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel–prednisone in metastatic castration-resistant prostate cancer (2015) (16)
Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA) (2019) (16)
Impact of Protein Stability, Cellular Localization, and Abundance on Proteomic Detection of Tumor-Derived Proteins in Plasma (2011) (15)
Single cell dynamic phenotyping (2016) (15)
A phase III, randomized, double-blind, multicenter trial comparing the investigational agent orteronel (TAK-700) plus prednisone (P) with placebo plus P in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy. (2012) (14)
JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines (2017) (14)
Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. (2004) (14)
Beta‐2‐microglobulin expression correlates with high‐grade prostate cancer and specific defects in androgen signaling (2010) (12)
A phase I/II study of safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Updated phase II results. (2013) (12)
Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study (2011) (12)
Phase I trial of RAD001 (R), bevacizumab (B), and docetaxel (D) for castration-resistant prostate cancer (CRPC). (2009) (11)
Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration‐resistant Prostate Cancer (CRPC) (2017) (11)
MultiCellDS: a community-developed standard for curating microenvironment-dependent multicellular data (2016) (11)
The Long-Term Benefits of Increased Aspirin Use by At-Risk Americans Aged 50 and Older (2016) (11)
MultiCellDS: a standard and a community for sharing multicellular data (2016) (10)
A perspective on protein profiling of blood (2005) (9)
Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma (2016) (9)
Intracellular kinetics of the androgen receptor shown by multimodal Image Correlation Spectroscopy (mICS) (2016) (8)
Safety, efficacy, and pharmacodynamics of the investigational agent orteronel (TAK-700) in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study. (2012) (7)
Cancer Moonshot 2.0. (2021) (7)
The sciences converge to fight cancer (2012) (7)
Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition (2012) (6)
PPAR? Signaling: One Size Fits All? (2004) (5)
Phase I results from a phase I/II study of orteronel, an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC). (2012) (5)
Efficacy and safety of single agent pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in hormone refractory prostate cancer after failure of taxane-based therapy (2005) (5)
Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel. (2014) (5)
Rapid changes in circulating tumor cells following anti-angiogenic therapy (2015) (4)
Stochasticity and determinism in cancer creation and progression. (2016) (4)
Obesity, ethnicity, and surgical outcomes for clinically localized prostate cancer (2005) (4)
Genitourinary tumors, prostate (2012) (3)
HER‐Kinase‐Directed Therapy of Prostate Cancer (2001) (3)
Cancer Xenograft Model CWR 22-R Nonresponsive Genes in the Androgen-independent Prostate Dysregulated Expression of Androgen-responsive and Updated Version (2000) (3)
Abstract 540: Deep learning to determine breast cancer estrogen receptor status from nuclear morphometric features in H&E images (2017) (3)
Chemical Consequences Resulting from Multi-millicurie Preparation of 6-[18F]-Fluoro-6-deoxy-L-ascorbic Acid (1997) (3)
Vaccination with CD 20 peptides induces a biologically active , specific immune response in mice (2002) (2)
Microbes Battle Back (1997) (2)
PPARgamma signaling: one size fits all? (2004) (2)
Safety and efficacy of everolimus (E), bevacizumab (B), and docetaxel (D) for castration resistant prostate cancer (CRPC). (2015) (2)
Ductal adenocarcinoma of the prostate. (2004) (2)
7014 POSTER DISCUSSION Evaluation of Circulating Tumour Cells (CTCs) in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Receiving TAK-700, an Investigational 17,20-lyase Inhibitor (2011) (2)
Structure‐Based Androgen Receptor Gene Mutation Database: A Tool to Link Molecular Location and Receptor Function (2002) (1)
565 POSTER Activity of the anti-IGF-IR antibody CP-751,871 in combination with docetaxel as first-line treatment for castration resistant prostate cancer in a randomized Phase II trial (2008) (1)
High-throughput microscopy reveals the impact of multifactorial environmental perturbations on colorectal cancer cell growth (2021) (1)
Sequential monitoring of androgen receptor expression and copy number variation in castration-resistant prostate cancer (CRPC). (2013) (1)
Personalized genetics: a responsible approach. (2008) (1)
THE DOCTOR WILL SEE YOU (AND YOUR DATA) NOW. (2016) (1)
Abstract #LB-259: A pilot study utilizing molecular profiling of patients\#8217; tumors to find potential targets and select treatments for their refractory cancers (2009) (1)
Phase II trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer. (2020) (1)
Epidermal growth factor receptor dimerization status determines response to HER-kinase targeted therapies in keratinocytes. (2004) (1)
COVID-19 and other adult vaccines can drive global disease prevention (2022) (1)
355 IMPACT OF “IMAGE-GUIDED TARGETED BIOPSY” ON THE FOLLOW-UP SURVEILLANCE PROSTATE BIOPSY TO DETERMINE PROGRESSION AMONG MEN ON ACTIVE SURVEILLANCE (2012) (1)
P114 Safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Phase 2 results from a phase 1/2 study (2012) (1)
Reframe the health debate. (2012) (0)
Stimulation of the HER-kinase axis promotes resistance to the Raf-kinase activity of sorafenib, which can be reversed by the addition of MEK inhibitor U0126 (2007) (0)
Circulating tumor cell enumeration combined with gene expression analysis and clinical variables in castrate resistant prostate cancer (2008) (0)
A longitudinal assessment of treatment-related differences in quality of life among prostate cancer patients (2007) (0)
Integration of Pathology, Radiology, and in vitro Data in Patient-Calibrated Cancer Simula- tions: Recent Advances and Future Outlook for Ductal Carcinoma In Situ (DCIS) (2012) (0)
Book Review (2000) (0)
Abstract 1648: Deep learning tissue "fingerprints" to identify patients and predict clinical subtypes of breast cancer from digital pathology images (2019) (0)
Abstract PR16: Spatio-temporal heterogeneity in the tumor microenvironment influences the evolutionary dynamics of drug resistance (2015) (0)
TheCurrent State of Preclinical ProstateCancerAnimalModels (2008) (0)
Correlating nuclear morphometric patterns with estrogen receptor status in breast cancer pathologic specimens (2018) (0)
Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma (2016) (0)
Phase 2 Results from a Phase 1/2 Study of Tak-700 (ORTERONEL), An Oral, Investigational, Nonsteroidal 17,20-Lyase Inhibitor, with Docetaxel and Prednisone (DP) in Metastatic Castration-Resistant Prostate Cancer (MCRPC) (2012) (0)
Models for Prostate Cancer (2007) (0)
Abstract B36: Interrogating cellular metabolism to improve therapy for EGFR mutant NSCLC (2016) (0)
Biomarkers and obesity in surgically treated patients with prostate cancer. (2006) (0)
Advances in Brief 17-Allylamino-17-demethoxygeldanamycin Induces the Degradation of Androgen Receptor and HER-2 / neu and Inhibits the Growth of Prostate Cancer Xenografts 1 (2002) (0)
Abstract 2414: Interrogating cellular metabolism reveals mTORC2 as a new biomarker to stratify epidermal growth factor receptor-mutant non-small cell lung cancer (2018) (0)
707 Penetration of the Blood-Brain-Barrier by Oxidized Vitamin C Improves Outcome in Both Reperfused and Non-Reperfused Stroke (2000) (0)
Abstract 5295: Toward high throughput immune infiltrate analysis from H&E stained images (2018) (0)
Abstract 3934: Bladder cancer tumor heterogeneity: development of a system-level mutation assay (2017) (0)
Applications of Proteomics in Prostate Cancer (2010) (0)
Quantitative Proteomic Pro fi ling Identi fi esProteinCorrelates to EGFR Kinase Inhibition (2012) (0)
Abstract 3731: A novel multidimensional cfDNA assay for real time analysis of chemotherapy response (2017) (0)
Functional dissection of transcriptional profiles in androgen-dependent and -independent prostate cancer (2001) (0)
Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA) (2019) (0)
Functional dissection of transcriptional profiles in androgen-dependent and -independent prostate cancer (2001) (0)
Method for treating prostate cancer in a human, article of manufacture and the use of an antibody which binds ErbB2 (2000) (0)
Positron Emission Tomography of a Human Prostate Cancer Xenograft : Association of Changes in Deoxyglucose Accumulation with Other Measures of Outcome following Androgen Withdrawal 1 (2006) (0)
Advances in Brief Response of Prostate Cancer to Anti-Her-2 / neu Antibody in Androgen-dependent and-independent Human Xenograft Models 1 (1999) (0)
Mathematical Oncology Multiparameter Computational Modeling of Tumor Invasion (2009) (0)
Deep learned tissue “fingerprints” classify breast cancers by ER/PR/Her2 status from H&E images (2020) (0)
Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer (2020) (0)
Paradoxical androgen receptor regulation by small molecule enantiomers (2020) (0)

This paper list is powered by the following services:

Other Resources About David Agus

en.wikipedia.org

What Schools Are Affiliated With David Agus?

David Agus is affiliated with the following schools:

Image Attributions

Image Source for David Agus